hydrazine has been researched along with Marchiafava-Micheli Syndrome in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Advani, A; Barot, SV; Carraway, HE; Kalaycio, M; Kerr, C; Kuzmanovic, T; Lee, S; Lichtin, A; Maciejewski, JP; Patel, BJ; Patel, S; Przychodzen, BP; Radivoyevitch, T; Sekeres, MA; Thota, S | 1 |
| Babushok, DV; Sun, L | 1 |
| Kulasekararaj, AG; Marsh, JC | 1 |
| Höchsmann, B; Körper, S; Schrezenmeier, H | 1 |
| Bown, N; Cavenagh, J; Dokal, I; Foukaneli, T; Hill, A; Hillmen, P; Ireland, R; Killick, SB; Kulasekararaj, A; Marsh, JC; Mufti, G; Samarasinghe, S; Snowden, JA; Wood, A | 1 |
| Bucher, U; Kummer, H | 1 |
2 review(s) available for hydrazine and Marchiafava-Micheli Syndrome
| Article | Year |
|---|---|
Management of the refractory aplastic anemia patient: what are the options?
Topics: Adult; Age Factors; Alemtuzumab; Allografts; Anemia, Aplastic; Antibodies, Monoclonal, Humanized; Antilymphocyte Serum; Antineoplastic Agents; Benzoates; Bone Marrow Diseases; Bone Marrow Failure Disorders; Cyclosporine; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Hemoglobinuria, Paroxysmal; Humans; Hydrazines; Immunosuppression Therapy; Immunosuppressive Agents; Middle Aged; Pyrazoles; Siblings; Survival Rate; Unrelated Donors | 2013 |
[Aplastic anemia].
Topics: Anemia, Aplastic; Antilymphocyte Serum; Benzoates; DNA Mutational Analysis; Drug Therapy, Combination; Early Medical Intervention; Hematopoietic Stem Cell Transplantation; Hemoglobinuria, Paroxysmal; Humans; Hydrazines; Immunosuppressive Agents; Myelodysplastic Syndromes; Prognosis; Pyrazoles; Randomized Controlled Trials as Topic; Shelterin Complex; Telomerase; Telomere-Binding Proteins; Transplantation Conditioning | 2014 |
4 other study(ies) available for hydrazine and Marchiafava-Micheli Syndrome
| Article | Year |
|---|---|
Distinctive and common features of moderate aplastic anaemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Algorithms; Anemia, Aplastic; Autoimmune Diseases; Benzoates; Blood Transfusion; Bone Marrow; Child; Child, Preschool; Clonal Evolution; Combined Modality Therapy; Danazol; Disease Management; Disease Progression; Female; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Hemoglobinuria, Paroxysmal; Humans; Hydrazines; Immunosuppressive Agents; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Pyrazoles; Severity of Illness Index; Young Adult | 2020 |
Secondary myelodysplastic syndrome and leukemia in acquired aplastic anemia and paroxysmal nocturnal hemoglobinuria.
Topics: Age of Onset; Anemia, Aplastic; Antibodies, Monoclonal, Humanized; Benzoates; Bone Marrow; Chromosome Aberrations; Chromosomes, Human, Pair 7; Clonal Evolution; Clone Cells; Disease Progression; Granulocyte Colony-Stimulating Factor; Hemoglobinuria, Paroxysmal; Humans; Hydrazines; Leukemia, Myeloid, Acute; Models, Biological; Monosomy; Mutation; Myelodysplastic Syndromes; Oncogene Proteins, Fusion; Pyrazoles; Selection, Genetic; Telomere Shortening | 2020 |
Guidelines for the diagnosis and management of adult aplastic anaemia.
Topics: Aged; Anemia, Aplastic; Benzoates; Blood Component Transfusion; Female; Hematopoietic Stem Cell Transplantation; Hemoglobinuria, Paroxysmal; Humans; Hydrazines; Immunosuppressive Agents; Opportunistic Infections; Pregnancy; Pregnancy Complications, Hematologic; Pyrazoles; Severity of Illness Index | 2016 |
[Experiences with a new cytostatic of the methylhydrazine series (Natulan). With special reference to hematological side-effects].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Female; Hemodynamics; Hemoglobinuria, Paroxysmal; Humans; Hydrazines; Male; Middle Aged; Neoplasms | 1965 |